Do analysts rate BCDA or TCRT?

BioCardia presently has a consensus price target of $25.00, indicating a potential upside of 3,017.21%. Given BioCardia's stronger consensus rating and higher possible upside, equities analysts clearly believe BioCardia is more favorable than Alaunos Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioCardia 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Alaunos Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is BCDA or TCRT more profitable?

Alaunos Therapeutics' return on equity of -165.94% beat BioCardia's return on equity. Company Net Margins Return on Equity Return on Assets BioCardia N/A -5,456.14% -232.75% Alaunos Therapeutics N/A -165.94% -123.50%

Is TIL or BCDA more profitable?

Instil Bio's return on equity of -39.76% beat BioCardia's return on equity. Company Net Margins Return on Equity Return on Assets Instil Bio N/A -39.76% -22.38% BioCardia N/A -5,456.14% -232.75%

Which has better earnings & valuation, BCDA or ATHE?

Alterity Therapeutics has lower revenue, but higher earnings than BioCardia. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BioCardia $60K 152.11 -$8.23M -$0.91 N/A Alterity Therapeutics N/A N/A -$7.87M N/A N/A

Is BCDA or ATHE more profitable?

Alterity Therapeutics' return on equity of 0.00% beat BioCardia's return on equity. Company Net Margins Return on Equity Return on Assets BioCardia N/A -5,456.14% -232.75% Alterity Therapeutics N/A N/A N/A

Do analysts prefer IZTC or BCDA?

BioCardia has a consensus target price of $25.00, indicating a potential upside of 3,017.21%. Given BioCardia's stronger consensus rating and higher probable upside, analysts clearly believe BioCardia is more favorable than Invizyne Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Invizyne Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 BioCardia 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger earnings & valuation, IZTC or BCDA?

Invizyne Technologies has higher earnings, but lower revenue than BioCardia. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Invizyne Technologies N/A N/A N/A N/A N/A BioCardia $60K 152.11 -$8.23M -$0.91 N/A

Is IZTC or BCDA more profitable?

Invizyne Technologies' return on equity of 0.00% beat BioCardia's return on equity. Company Net Margins Return on Equity Return on Assets Invizyne Technologies N/A N/A N/A BioCardia N/A -5,456.14% -232.75%

Is MREO or BCDA more profitable?

Mereo BioPharma Group's return on equity of -81.28% beat BioCardia's return on equity. Company Net Margins Return on Equity Return on Assets Mereo BioPharma Group N/A -81.28% -70.45% BioCardia N/A -5,456.14% -232.75%

BioCardia (BCDA) Competitors

$0.80 -0.11 (-11.89%)

Closing price 07/14/2026 04:00 PM Eastern

Extended Trading

$0.86 +0.06 (+7.11%)

As of 04:09 AM Eastern

Compare

BCDA vs. TCRT, TIL, ATHE, IZTC, and MREO

Should you buy BioCardia stock or one of its competitors? MarketBeat compares BioCardia with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BioCardia include Alaunos Therapeutics (TCRT), Instil Bio (TIL), Alterity Therapeutics (ATHE), Invizyne Technologies (IZTC), and Mereo BioPharma Group (MREO). These companies are all part of the "pharmaceutical products" industry.

How does BioCardia compare to Alaunos Therapeutics?

BioCardia (NASDAQ:BCDA) and Alaunos Therapeutics (NASDAQ:TCRT) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, media sentiment, analyst recommendations, dividends and profitability.

BioCardia presently has a consensus price target of $25.00, indicating a potential upside of 3,017.21%. Given BioCardia's stronger consensus rating and higher possible upside, equities analysts clearly believe BioCardia is more favorable than Alaunos Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCardia	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Alaunos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

BioCardia has a beta of 0.44, suggesting that its stock price is 56% less volatile than the broader market. Comparatively, Alaunos Therapeutics has a beta of -1.02, suggesting that its stock price is 202% less volatile than the broader market.

20.6% of BioCardia shares are held by institutional investors. Comparatively, 27.7% of Alaunos Therapeutics shares are held by institutional investors. 17.4% of BioCardia shares are held by company insiders. Comparatively, 16.1% of Alaunos Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Alaunos Therapeutics' return on equity of -165.94% beat BioCardia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioCardia	N/A	-5,456.14%	-232.75%
Alaunos Therapeutics	N/A	-165.94%	-123.50%

In the previous week, BioCardia had 3 more articles in the media than Alaunos Therapeutics. MarketBeat recorded 4 mentions for BioCardia and 1 mentions for Alaunos Therapeutics. Alaunos Therapeutics' average media sentiment score of 1.87 beat BioCardia's score of 0.78 indicating that Alaunos Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
BioCardia	Positive
Alaunos Therapeutics	Very Positive

Alaunos Therapeutics has lower revenue, but higher earnings than BioCardia. Alaunos Therapeutics is trading at a lower price-to-earnings ratio than BioCardia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCardia	$60K	152.11	-$8.23M	-$0.91	N/A
Alaunos Therapeutics	N/A	N/A	-$4.18M	-$2.13	N/A

Summary

BioCardia beats Alaunos Therapeutics on 9 of the 14 factors compared between the two stocks.

How does BioCardia compare to Instil Bio?

Instil Bio (NASDAQ:TIL) and BioCardia (NASDAQ:BCDA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, earnings, profitability, media sentiment, analyst recommendations and risk.

BioCardia has higher revenue and earnings than Instil Bio. Instil Bio is trading at a lower price-to-earnings ratio than BioCardia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Instil Bio	N/A	N/A	-$71.37M	-$7.08	N/A
BioCardia	$60K	152.11	-$8.23M	-$0.91	N/A

60.6% of Instil Bio shares are held by institutional investors. Comparatively, 20.6% of BioCardia shares are held by institutional investors. 47.0% of Instil Bio shares are held by company insiders. Comparatively, 17.4% of BioCardia shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Instil Bio's return on equity of -39.76% beat BioCardia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Instil Bio	N/A	-39.76%	-22.38%
BioCardia	N/A	-5,456.14%	-232.75%

Instil Bio presently has a consensus price target of $66.00, indicating a potential upside of 743.99%. BioCardia has a consensus price target of $25.00, indicating a potential upside of 3,017.21%. Given BioCardia's stronger consensus rating and higher probable upside, analysts clearly believe BioCardia is more favorable than Instil Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Instil Bio	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
BioCardia	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, BioCardia had 3 more articles in the media than Instil Bio. MarketBeat recorded 4 mentions for BioCardia and 1 mentions for Instil Bio. Instil Bio's average media sentiment score of 1.87 beat BioCardia's score of 0.78 indicating that Instil Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Instil Bio	Very Positive
BioCardia	Positive

Instil Bio has a beta of 1.9, suggesting that its share price is 90% more volatile than the broader market. Comparatively, BioCardia has a beta of 0.44, suggesting that its share price is 56% less volatile than the broader market.

Summary

BioCardia beats Instil Bio on 8 of the 14 factors compared between the two stocks.

How does BioCardia compare to Alterity Therapeutics?

BioCardia (NASDAQ:BCDA) and Alterity Therapeutics (NASDAQ:ATHE) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings, media sentiment and analyst recommendations.

In the previous week, BioCardia had 1 more articles in the media than Alterity Therapeutics. MarketBeat recorded 4 mentions for BioCardia and 3 mentions for Alterity Therapeutics. BioCardia's average media sentiment score of 0.78 beat Alterity Therapeutics' score of 0.29 indicating that BioCardia is being referred to more favorably in the media.

Company	Overall Sentiment
BioCardia	Positive
Alterity Therapeutics	Neutral

Alterity Therapeutics' return on equity of 0.00% beat BioCardia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioCardia	N/A	-5,456.14%	-232.75%
Alterity Therapeutics	N/A	N/A	N/A

20.6% of BioCardia shares are owned by institutional investors. Comparatively, 2.1% of Alterity Therapeutics shares are owned by institutional investors. 17.4% of BioCardia shares are owned by insiders. Comparatively, 38.8% of Alterity Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

BioCardia presently has a consensus price target of $25.00, indicating a potential upside of 3,017.21%. Alterity Therapeutics has a consensus price target of $13.00, indicating a potential upside of 158.45%. Given BioCardia's higher possible upside, analysts plainly believe BioCardia is more favorable than Alterity Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCardia	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Alterity Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Alterity Therapeutics has lower revenue, but higher earnings than BioCardia.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCardia	$60K	152.11	-$8.23M	-$0.91	N/A
Alterity Therapeutics	N/A	N/A	-$7.87M	N/A	N/A

BioCardia has a beta of 0.44, suggesting that its share price is 56% less volatile than the broader market. Comparatively, Alterity Therapeutics has a beta of 0.25, suggesting that its share price is 75% less volatile than the broader market.

Summary

BioCardia and Alterity Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does BioCardia compare to Invizyne Technologies?

Invizyne Technologies (NASDAQ:IZTC) and BioCardia (NASDAQ:BCDA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, media sentiment, valuation, profitability and analyst recommendations.

BioCardia has a consensus target price of $25.00, indicating a potential upside of 3,017.21%. Given BioCardia's stronger consensus rating and higher probable upside, analysts clearly believe BioCardia is more favorable than Invizyne Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Invizyne Technologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
BioCardia	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, BioCardia had 3 more articles in the media than Invizyne Technologies. MarketBeat recorded 4 mentions for BioCardia and 1 mentions for Invizyne Technologies. BioCardia's average media sentiment score of 0.78 beat Invizyne Technologies' score of 0.00 indicating that BioCardia is being referred to more favorably in the news media.

Company	Overall Sentiment
Invizyne Technologies	Neutral
BioCardia	Positive

Invizyne Technologies has higher earnings, but lower revenue than BioCardia.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Invizyne Technologies	N/A	N/A	N/A	N/A	N/A
BioCardia	$60K	152.11	-$8.23M	-$0.91	N/A

Invizyne Technologies' return on equity of 0.00% beat BioCardia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Invizyne Technologies	N/A	N/A	N/A
BioCardia	N/A	-5,456.14%	-232.75%

20.6% of BioCardia shares are held by institutional investors. 17.4% of BioCardia shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

BioCardia beats Invizyne Technologies on 8 of the 10 factors compared between the two stocks.

How does BioCardia compare to Mereo BioPharma Group?

Mereo BioPharma Group (NASDAQ:MREO) and BioCardia (NASDAQ:BCDA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, media sentiment, earnings, risk and dividends.

BioCardia has lower revenue, but higher earnings than Mereo BioPharma Group. Mereo BioPharma Group is trading at a lower price-to-earnings ratio than BioCardia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mereo BioPharma Group	$500K	100.24	-$41.88M	-$0.05	N/A
BioCardia	$60K	152.11	-$8.23M	-$0.91	N/A

62.8% of Mereo BioPharma Group shares are held by institutional investors. Comparatively, 20.6% of BioCardia shares are held by institutional investors. 6.5% of Mereo BioPharma Group shares are held by insiders. Comparatively, 17.4% of BioCardia shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, BioCardia had 3 more articles in the media than Mereo BioPharma Group. MarketBeat recorded 4 mentions for BioCardia and 1 mentions for Mereo BioPharma Group. Mereo BioPharma Group's average media sentiment score of 1.87 beat BioCardia's score of 0.78 indicating that Mereo BioPharma Group is being referred to more favorably in the media.

Company	Overall Sentiment
Mereo BioPharma Group	Very Positive
BioCardia	Positive

Mereo BioPharma Group presently has a consensus target price of $3.25, suggesting a potential upside of 935.03%. BioCardia has a consensus target price of $25.00, suggesting a potential upside of 3,017.21%. Given BioCardia's higher possible upside, analysts clearly believe BioCardia is more favorable than Mereo BioPharma Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mereo BioPharma Group	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25
BioCardia	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Mereo BioPharma Group's return on equity of -81.28% beat BioCardia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mereo BioPharma Group	N/A	-81.28%	-70.45%
BioCardia	N/A	-5,456.14%	-232.75%

Mereo BioPharma Group has a beta of 0.35, indicating that its stock price is 65% less volatile than the broader market. Comparatively, BioCardia has a beta of 0.44, indicating that its stock price is 56% less volatile than the broader market.

Summary

Mereo BioPharma Group beats BioCardia on 8 of the 15 factors compared between the two stocks.

Get BioCardia News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BCDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BCDA vs. The Competition

Export

Metric	BioCardia	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$10.35M	$3.68B	$6.86B	$12.44B
Dividend Yield	N/A	2.19%	2.68%	8.42%
P/E Ratio	-0.88	20.98	27.01	24.38
Price / Sales	152.11	311.10	519.43	91.92
Price / Cash	N/A	143.66	48.59	59.36
Price / Book	10.03	8.54	10.80	6.33
Net Income	-$8.23M	$23.83M	$3.59B	$331.02M
7 Day Performance	-16.91%	-2.77%	-1.47%	-0.33%
1 Month Performance	-3.73%	5.85%	2.78%	-1.29%
1 Year Performance	-64.82%	52.15%	28.50%	21.30%

BioCardia Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BCDA BioCardia	4.1034 of 5 stars	$0.80 -11.9%	$25.00 +3,017.2%	-65.6%	$10.35M	$60K	N/A	40	News Coverage
TCRT Alaunos Therapeutics	0.5743 of 5 stars	$2.04 -5.1%	N/A	-47.8%	$52.51M	N/A	N/A	40	Positive News
TIL Instil Bio	1.6943 of 5 stars	$7.75 +0.4%	$66.00 +751.6%	-68.1%	$52.36M	N/A	N/A	410
ATHE Alterity Therapeutics	3.5411 of 5 stars	$5.49 -6.8%	$13.00 +136.8%	+8.6%	$52.23M	N/A	N/A	10	Positive News Gap Up
IZTC Invizyne Technologies	N/A	$8.14 -4.0%	N/A	-35.1%	$50.89M	N/A	N/A	29

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BCDA) was last updated on 7/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioCardia (BCDA) Competitors

BCDA vs. TCRT, TIL, ATHE, IZTC, and MREO

How does BioCardia compare to Alaunos Therapeutics?

Summary

How does BioCardia compare to Instil Bio?

Summary

How does BioCardia compare to Alterity Therapeutics?

Summary

How does BioCardia compare to Invizyne Technologies?

Summary

How does BioCardia compare to Mereo BioPharma Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCDA vs. The Competition

BioCardia Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioCardia (BCDA) Competitors

BCDA vs. TCRT, TIL, ATHE, IZTC, and MREO

How does BioCardia compare to Alaunos Therapeutics?

Do analysts rate BCDA or TCRT?

Which has more volatility and risk, BCDA or TCRT?

Do institutionals & insiders have more ownership in BCDA or TCRT?

Is BCDA or TCRT more profitable?

Does the media favor BCDA or TCRT?

Which has stronger valuation and earnings, BCDA or TCRT?

Summary

How does BioCardia compare to Instil Bio?

Which has better valuation and earnings, TIL or BCDA?

Do insiders & institutionals believe in TIL or BCDA?

Is TIL or BCDA more profitable?

Do analysts prefer TIL or BCDA?

Does the media refer more to TIL or BCDA?

Which has more risk and volatility, TIL or BCDA?

Summary

How does BioCardia compare to Alterity Therapeutics?

Does the media prefer BCDA or ATHE?

Is BCDA or ATHE more profitable?

Do institutionals & insiders believe in BCDA or ATHE?

Do analysts prefer BCDA or ATHE?

Which has better earnings & valuation, BCDA or ATHE?

Which has more risk & volatility, BCDA or ATHE?

Summary

How does BioCardia compare to Invizyne Technologies?

Do analysts prefer IZTC or BCDA?

Does the media favor IZTC or BCDA?

Which has stronger earnings & valuation, IZTC or BCDA?

Is IZTC or BCDA more profitable?

Do insiders and institutionals believe in IZTC or BCDA?

Summary

How does BioCardia compare to Mereo BioPharma Group?

Which has higher valuation & earnings, MREO or BCDA?

Do insiders & institutionals have more ownership in MREO or BCDA?

Does the media favor MREO or BCDA?

Do analysts prefer MREO or BCDA?

Is MREO or BCDA more profitable?

Which has more volatility & risk, MREO or BCDA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCDA vs. The Competition

BioCardia Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools